ACS Biomaterials Science & Engineering · 2022 · 25 citations · 27 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyChemotherapyProdrug DesignAnticancer Prodrug DesignCombination ChemotherapyCytotoxic ChemotherapyMulti-target Drug DesignTargeted TherapyTargeting LigandsAntiproliferative AgentsAntiproliferative Drug ActionChemotherapeutic Prodrug DesignCopper Transporter 1 (Ctr1)Defective Dna Repair PathwaysPlatinum CompoundsPlatinum-based AgentsTriple-negative Breast Cancer Therapy
Triple-negative breast cancer (TNBC) cells show improved sensitivity for cisplatin therapy due to their defective DNA damage repair system. However, the clinical utilization of cisplatin is limited by dose-dependent systemic toxicities and chemoresistance. Cisplatin Pt(IV) derivatives having kinetically inert octahedral geometry provide an effective strategy to overcome these limitations. Upon cellular reduction, these derivatives release cisplatin and axial ligands, acting as dual-action prodrugs. Hereby, we have developed three cisplatin(IV) conjugates using distinct bioactive axial moieties (valproate, tocopherol, and chlorambucil), which can synergistically complement cisplatin activity and attack multiple cellular targets. The designed derivatives showcased enhanced antiproliferative activity and improved therapeutic synergism along with a noteworthy cisplatin dose reduction index in a panel of six cancer cells. These Pt(IV) derivatives remarkably improved cellular drug uptake and showed lower dependency on copper transporter 1 (Ctr1) for uptake than cisplatin. The results of enhanced in vitro activity were well corroborated by in vivo efficacy testing in the 4T1 cell-based TNBC model, showcasing ∼2-7-folds higher tumor volume reduction for Pt(IV) derivatives than cisplatin. In addition, the designed derivatives significantly reduced the nephrotoxicity risk involved in cisplatin therapy, indicated by systemic toxicity biomarkers and organ histopathology. The results indicated that cisplatin(IV) derivatives could open new avenues for safer synergistic chemotherapy in TNBC.
27
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
Rebecca Dent, Maureen Trudeau, Kathleen I. Pritchard et al. · Clinical Cancer Research · 2007 · 5.1K citations · Full text
Sulforhodamine B colorimetric assay for cytotoxicity screening
Vanicha Vichai, Kanyawim Kirtikara · Nature Protocols · 2006 · 3.7K citations